OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index
17 Octobre 2024 - 6:00PM
NANTES, France, October 17, 6:00pm CET -
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo:
OSE), today announced it will be presenting its novel
OSE-CYTOMASK Cis-Demasking1 cytokine technology in oral
presentations selected for international conferences:
- The Festival of
Biologics in Basel, Switzerland (October 17, 2024)
- The 16th Annual
Protein & Antibody Engineering Summit (PEGS) Europe Summit in
Barcelona, Spain (November 7, 2024)
- The Antibody
Therapeutics Xchange in Brussels (November 18, 2024)
OSE-CYTOMASK is an innovative proprietary
non-cleavable linker technology to create a new class of regulated
and targeted cytokine therapeutics that deliver highly active
medicines with improved therapeutic index. The presentations
highlight the rational design of the technology through two first
preclinical programs based on anti-PD1 masked cytokine (IL-2,
IL-15) in oncology with conditional Cis-Demasking and
Cis-Potentiation of tumor-specific T cells expressing PD1 or other
immune targets.
Aurore Morello, Head of Research, OSE
Immunotherapeutics, said: “We are very happy to present
our novel OSE-CYTOMASK technology at upcoming leading scientific
conferences. Our novel linker technology allows conditional
Cis-Demasking of cytokine, through PD1-targeting on tumor-specific
T cells, without relying on protease-cleavable technology or
mutagenesis of cytokine to abrogate off-tumor activity associated
with significant toxicity of the majority of cytokines from this
class of drugs. The high preclinical efficacy observed in
monotherapy and good tolerance profile of the first two drug
candidates selected open the way to a potential novel
first-in-class treatment for patients in high need of new
therapeutic options in oncology.”
Nicolas Poirier, Chief Executive
Officer, OSE Immunotherapeutics, adds: “We are proud of
the achievements from our research team on the advancement of these
programs. This highly innovative technology promises to unleash the
full potential of cytokines in oncology by dramatically increasing
the therapeutic index of this class of drugs. We are also
interested in potential applications of this innovative technology
in autoimmune and inflammatory diseases.”
Immunostimulatory cytokines are a highly potent
class of drug to reactivate the immune system against tumors. Their
narrow therapeutic index is associated with significant peripheral
toxicity and limited drug exposure in the tumor microenvironment
(TME), limiting their clinical development.
Current conditional cytokine masking approaches
relying on theoretical demasking activity in the TME with cleavable
linker technologies by enzymes produce more selectively by the
tumors have already demonstrated their limitation due to the
heterogenous protease expression in tumors (variable on-tumor
activation across patients) and non-specific protease expression in
non-tumor sites (off-tumor cytokine activity). We have engineered
an innovative non-cleavable recombinant linker technology allowing
specific conditional delivery of cytokine activity only where
needed based on an original targeted Cis-Demasking mechanism
independent of proteases expression.
OSE-CYTOMASK technology has been used first to
implement our proprietary anti-PD1 BiCKI® platform in order to
improve the therapeutic index of highly active cytokines (eg.,
IL-2, IL-15…). The Company presented two first preclinical programs
with anti-PD1/masked IL-2 and anti PD1/masked IL-15 with robust
preclinical efficacy demonstrated in monotherapy leading to a high
rate of anti-tumor response and eradication in different models
(eg. orthotopic pancreatic tumor, melanoma or colon cancer) in the
absence of peripheral toxicity in dose-response illustrating
significantly improved therapeutic index of both IL-2 or IL-15
using the OSE-CYTOMASK technology.
Presentations: details
Festival of Biologics (October 17),
BaselPresenter: Aurore Morello, PhD., Head of Research,
OSE Immunotherapeutics“OSE- Cytomask Technology:
Cis-Demasking Cytokine Technology for targeted
Delivery”October 17, 11:30
Protein & Antibody Engineering Summit (PEGS) Europe
Summit (November 7),
Barcelona Presenter: Nicolas Poirier, PhD, Chief Executive
Officer, OSE Immunotherapeutics“OSE-CYTOMASK: Cis-Demasking
Cytokine Technology with Non-Cleavable Linker”November 7,
16:40
Antibody Therapeutics Xchange (November
18), Brussels Presenter:
Aurore Morello, PhD., Head of Research, OSE
Immunotherapeutics“Addressing challenges faced for optimal
bi-specific and Immunocytokines engineering” November 18,
09:05 - 10:05
About OSE Immunotherapeutics
OSE Immunotherapeutics is a biotech company
dedicated to developing first-in-class assets in immuno-oncology
(IO) and immuno-inflammation (I&I). The Company’s current
well-balanced first-in-class clinical pipeline includes:
-
Tedopi® (immunotherapy activating
tumor specific T-cells, off-the-shelf, neoepitope-based): most
advanced therapeutic cancer vaccine in development; positive
results from a randomized Phase 3 trial (Atalante 1) in Non-Small
Cell Lung Cancer patients in third-line secondary resistance after
checkpoint inhibitor failure. Ongoing randomized registration Phase
3 study (Artemia) in second-line NSCLC in HLA-A2+ patients with
secondary resistance. Other Phase 2 trials, sponsored by clinical
oncology groups, of Tedopi® in combination are ongoing in solid
tumors.
- OSE-127 -
Lusvertikimab (humanized monoclonal antibody antagonist of IL-7
receptor); Positive Phase 2 (CoTikiS) study in Ulcerative Colitis;
ongoing preclinical research in leukemia.
- OSE-279
(anti-PD1): first positive results in the ongoing Phase 1/2 in
solid tumors.
- FR-104/VEL-101
(anti-CD28 monoclonal antibody): developed in partnership with
Veloxis Pharmaceuticals, Inc. in transplantation; ongoing Phase 1/2
in renal transplant (sponsor Nantes University Hospital);
successful Phase 1 in the US (sponsor Veloxis Pharmaceuticals,
Inc.).
- Anti-SIRPα monoclonal
antibody developed in partnership with Boehringer
Ingelheim in advanced solid tumors and
cardiovascular-renal-metabolic diseases (CRM); positive Phase 1
dose escalation results in monotherapy and in combination; Phase 2
in CRM diseases planned to be initiated end of 2024.
- ABBV-230 (ChemR23
agonist mAb) developed in partnership with AbbVie in chronic
inflammation.
OSE Immunotherapeutics expects to generate
further significant value from its three proprietary drug discovery
platforms, which are central to its ambitious goal to deliver
next-generation first-in-class immunotherapies:
- Pro-resolutive mAb
platform focused on targeting and advancing inflammation
resolution and optimizing the therapeutic potential of targeting
Neutrophils and Macrophages in I&I. ABBV-230
(licensed to AbbVie) is the first candidate generated by the
platform, additional discovery programs ongoing on new
pro-resolutive GPCRs.
- Myeloid Checkpoint
platform focused on optimizing the therapeutic potential
of myeloid cells in IO by targeting immune regulatory receptors
expressed by Macrophages and Dendritic cells. BI
765063 and BI 770371 (licensed to
Boehringer Ingelheim) are the most advanced candidates generated by
the platform. Ongoing additional discovery programs, in particular
with positive preclinical results obtained in monotherapy with new
anti-CLEC-1 mAbs.
-
BiCKI® Platform
is a bifunctional fusion protein platform built on the key backbone
component of anti-PD1 combined with a new immunotherapy target to
increase anti-tumor efficacy by “cis-potentiating” tumor-specific T
cells. A first program has been acquired by Boehringer Ingelheim.
OSE-CYTOMASK is an innovative technology to create
cytokine therapeutics with improved therapeutic index.
- mRNA Therapeutic
platform allows local delivery into the inflammatory site
of innovative immunotherapies encoded by RNA to locally controls
and/or suppress immune responses and inflammation.
Additional information about OSE
Immunotherapeutics assets is available on the Company’s website:
www.ose-immuno.com. Follow us on X and LinkedIn
Contacts
Sylvie
Détrysylvie.detry@ose-immuno.comNicolas PoirierChief Executive
Officer nicolas.poirier@ose-immuno.com |
French
Media: FP2COMFlorence
Portejoiefportejoie@fp2com.fr+33 6
07 768 283U.S. Media
ContactRooneyPartners LLCKate
Barrettekbarrette@rooneypartners.com+1 212 223 0561 |
|
Forward-looking statementsThis
press release contains express or implied information and
statements that might be deemed forward-looking information and
statements in respect of OSE Immunotherapeutics. They do not
constitute historical facts. These information and statements
include financial projections that are based upon certain
assumptions and assessments made by OSE Immunotherapeutics’
management in light of its experience and its perception of
historical trends, current economic and industry conditions,
expected future developments and other factors they believe to be
appropriate.These forward-looking statements include statements
typically using conditional and containing verbs such as “expect”,
“anticipate”, “believe”, “target”, “plan”, or “estimate”, their
declensions and conjugations and words of similar import. Although
the OSE Immunotherapeutics management believes that the
forward-looking statements and information are reasonable, the OSE
Immunotherapeutics’ shareholders and other investors are cautioned
that the completion of such expectations is by nature subject to
various risks, known or not, and uncertainties which are difficult
to predict and generally beyond the control of OSE
Immunotherapeutics. These risks could cause actual results and
developments to differ materially from those expressed in or
implied or projected by the forward-looking statements. These risks
include those discussed or identified in the public filings made by
OSE Immunotherapeutics with the AMF. Such forward-looking
statements are not guarantees of future performance. This press
release includes only summary information and should be read with
the OSE Immunotherapeutics Universal Registration Document filed
with the AMF on April 30, 2024, including the annual financial
report for the fiscal year 2023, available on the OSE
Immunotherapeutics’ website. Other than as required by applicable
law, OSE Immunotherapeutics issues this press release at the date
hereof and does not undertake any obligation to update or revise
the forward-looking information or statements.
1 Cis-Demasking: Bispecific antibodies (*) have
the capability to target cells either in a Cis- targeting (on the
same cell) or in a Trans-binding orientation (between two different
cells). Cis-Demasking bispecific technology targets two antigens
expressed on the same cell, with one masked modality (eg. Cytokine)
and enabling conditional activity of the cytokine on the desired
immune cell types upon antibody binding.
(*) Segués A. et al. International Review of
Cell and Molecular Biology 2022.
OSE Immunotherapeutics (EU:OSE)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
OSE Immunotherapeutics (EU:OSE)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024